Cardiac death is greater burden on global health. Fatal heart diseases involve formation of clots in major blood vessels, antiplatelet medicines can stop blood clots from forming. Anticoagulant therapy has established its place in reducing systemic thrombotic events in patients with atrial fibrillation. Efficacy of anticoagulant therapy has established its place in reducing systemic thrombotic events in patients with atrial fibrillation.
The MASTER DAPT trial unravels that abbreviated antiplatelet therapy was non-inferior to standard antiplatelet therapy with regard to net adverse clinical events. The trial evaluated abbreviated antiplatelet therapy compared with standard antiplatelet therapy among patients who underwent percutaneous coronary intervention (PCI) with a biodegradable-polymer sirolimus-eluting stent.
The Findings are published in American College of Cardiology.
Among patients with acute or chronic coronary artery disease who underwent percutaneous coronary intervention within the last 30-44 days and were at increased bleeding risk, abbreviated DAPT was non-inferior to standard DAPT regarding net adverse clinical events and major adverse cardiac or cerebral events.
The results of the trial were
• Net adverse clinical events (all-cause mortality, MI, stroke, or major bleeding) was 7.5% in the abbreviated therapy group compared with 7.7% in the standard therapy group (p < 0.001 for non inferiority)
• Major adverse cardiac or cerebral events (all-cause mortality, MI, or stroke) was 6.1% in the abbreviated therapy group compared with 5.9% in the standard therapy group (p = 0.001 for non inferiority)
• Major or clinically relevant non major bleeding was 6.5% in the abbreviated therapy group compared with 9.4% in the standard therapy group (p < 0.001 for superiority)
Trial concluded that abbreviated DAPT was superior to standard antiplatelet therapy regarding major or clinically relevant non-major bleeding. These results are specific to patients who received a biodegradable-polymer sirolimus-eluting stent. The results were the same among those with and without an indication for oral anticoagulation therapy.
Reference: https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2021/08/25/23/38/MASTER-DAPT